DRL-

Purpose-

Established in 1984, Dr. Reddy¶s Laboratories (NYSE: RDY) is an emerging global pharmaceutical
company.

As a fully integrated pharmaceutical company, their purpose is to provide affordable and innovative
medicines through their three core businesses:

Pharmaceutical Services and Ac tive Ingredients, comprising their Active Pharmaceuticals and
Custom Pharmaceuticals businesses;

Global Generics, which includes branded and unbranded generics; and

Proprietary Products, which includes New Chemical Entities (NCEs), Differentiated Formulations, and
Generic Biopharmaceuticals.
Their products are marketed globally, with a focus on India, US, Europe and Russia. Dr. Reddy¶s
conducts NCE research in the areas of metabolic disorders, cardiovas cular indications, anti -infectives
and inflammations.

Their strong portfolio of businesses, g eographies and products gives them an edge in an increasingly
competitive global market and allows them to provide affordable medication to people across the worl d,
regardless of geographic and socio -economic barriers.

Businesses-

Humanity¶s health needs are greater than any one company¶s ability to solve them; yet they can work
with others to bring new drugs quickly to the market and provide the building blocks of affordable
medicines. Through their PSAI business, which comprises the Active Pharmaceutical Ingredients (API)
and Custom Pharmaceutical Services (CPS) businesses, they offer IP advantaged, speedy product
development and cost-effective manufacturing se rvices to their customers ± generic companies and
innovators. This allows them to help make good medicines available to more people around the world.
The core strengths of their PSAI business are the state -of-the-art infrastructure, resources and skills
that they are able to offer to their customers:

Large and diverse product portfolio

Eight FDA-inspected plants and three technology centres

World class chemistry expertise

Robust, large-scale manufacturing capabilities

Intellectual Property (IP) driven product development for freedom to operate

Total, seamless supply chain management